glp-1 receptor agonists should be avoided in patients with Frontiers MYTH BUSTER #1 “Weight-loss injections

In addition, the study demonstrates that GLP-1 agonists are effective for weight loss irrespective of whether the patient has type 2 diabetes, and of the type of agonist used

Safety Issues of Tirzepatide (Pancreatitis and Gallbladder or Biliary Disease) in Type 2 Diabetes and Obesity: A Systematic Review and Meta-Analysis

Microneedles Microneedles (MNs) are minimally invasive devices engineered as micron-scale projections, typically ranging from 25 m to 2 mm in length

BMJ Group and Pharmaceutical Press: London, 2020

It is not uncommon for underwriters, even within the same carrier, to take different approaches when learning that an applicant is using these medications

As noted by others (Khan et al., 2020), it remains to be clarified if use of GLP-1 RAs is safe across the HF phenotypes